Phase 2 MIBC Clinical Trials
8 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–8 of 8 trials
Recruiting
Phase 2
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more
Tyra Biosciences, Inc90 enrolled35 locationsNCT06995677
Recruiting
Phase 1Phase 2
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
NMIBC
ImmunityBio, Inc.40 enrolled9 locationsNCT06800963
Recruiting
Phase 2
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
Muscle Invasive Bladder Cancer (MIBC)
Fujian Medical University Union Hospital25 enrolled12 locationsNCT07296705
Recruiting
Phase 2
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Theralase® Technologies Inc.90 enrolled16 locationsNCT03945162
Recruiting
Phase 1Phase 2
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)Clear Cell Renal Cell Cancer (ccRCC)+4 more
ITM Oncologics GmbH270 enrolled10 locationsNCT05706129
Recruiting
Phase 2Phase 3
Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)
Muscular Invasive Bladder Cancer (MIBC)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.840 enrolled1 locationNCT06879145
Recruiting
Phase 1Phase 2
A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC
High-risk NMIBC
Shanghai Hengrui Pharmaceutical Co., Ltd.150 enrolled1 locationNCT05410730
Recruiting
Phase 2
RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects
NMIBC
RemeGen Co., Ltd.85 enrolled1 locationNCT05943379